Table 1 Characteristics of the 56 patients and distribution according to treatment.
Variable | Total | Number of patients (%) | p-value | |
|---|---|---|---|---|
Pembrolizumab/Chemotherapy | Pembrolizumab | |||
Age | ||||
> 65 years | 37 (66.1) | 18 (64.2) | 19 (67.8) | 1 |
< 65 years | 19 (33.9) | 10 (35.8) | 9 (32.2) | |
Gender | ||||
Male | 41 (73.2) | 19 (67.8) | 22 (78.5) | 0.5 |
Female | 15 (26.8) | 9 (33.2) | 6 (21.5) | |
KRAS status | ||||
Wild-type | 43 (76.7) | 22 (78.5) | 21 (75.0) | 1 |
Mutated | 13 (23.3) | 6 (21.5) | 7 (25.0) | |
Number or metastatic sites | ||||
1–2 | 36 (64.2) | 19 (67.8) | 17 (60.7) | 0.7 |
> 2 | 20 (35.8) | 9 (33.2) | 11 (39.3) | |
CNS involvement | ||||
Positive | 16 (28.5) | 7 (25.0) | 9 (31.1) | 0.7 |
Negative | 40 (71.5) | 21(75.0) | 19 (68.9) | |
ECOG PS | ||||
0–1 | 46 (79.3) | 21 (75.0) | 25 (89.2) | 0.3 |
2 | 10 (20.7) | 7 (25.0) | 3 (10.8) | |
KRAS4A expression* | ||||
High | 28 (50.0) | 12 (42.9) | 16 (57.1) | 0.4 |
Low | 28 (50.0) | 16 (57.1) | 12 (42.9) | |
KRAS4B expression* | ||||
High | 31 (55.3) | 14 (50.0) | 17 (60.7) | 0.6 |
Low | 25 (44.7) | 14 (50.0) | 11 (39.3) | |
